Core Viewpoint - The company has responded to the regulatory inquiry regarding its 2024 annual report, addressing various aspects of its business performance and financial metrics, particularly focusing on revenue changes across different segments and the impact of market conditions on its operations [1][2]. Business Performance - In 2024, the company reported total revenue of 381.24 million yuan, with standardized model revenue at 164.77 million yuan, showing a year-on-year increase of 16.58%. However, model breeding revenue decreased by 8.60% to 90.06 million yuan, while drug efficacy evaluation and phenotypic analysis revenue increased by 7.14% to 53.20 million yuan [2][4]. - Domestic and international revenue were 325.43 million yuan and 53.06 million yuan respectively, with gross margins of 41.66% and 70.9%, indicating a 31.88% year-on-year growth in international revenue [2][4]. Revenue Analysis - The company conducted a volume and price analysis of revenue changes across different business segments, noting that the increase in standardized model revenue was due to a rise in project quantity, while the decline in customized model revenue was attributed to a decrease in project quantity [3][5]. - The company observed a general decline in project prices across all business types due to intensified market competition and increased customer price sensitivity [4][5]. Customer Segmentation - The customer base primarily consists of research and industrial clients, with research clients having a higher number but lower average transaction values compared to industrial clients [6][8]. - The revenue contribution from research clients and industrial clients remained stable year-on-year, with customized model business mainly serving research clients [6][8]. Gross Margin Comparison - The gross margin for standardized models increased by 7.26 percentage points, attributed to stable demand from research clients and improved cost control measures [7][9]. - The gross margin for breeding services decreased by 13.97 percentage points due to increased market competition and underutilization of breeding facilities, leading to higher unit costs [7][9]. International Business Growth - The company expanded its international market presence, resulting in significant revenue growth from overseas operations, with higher average sales prices compared to domestic sales [10][12]. - The gross margin for international sales was significantly higher than domestic sales, reflecting industry norms [10][12]. Inventory Management - As of the end of 2024, the company's inventory balance was 12.67 million yuan, a decrease of 19.95% year-on-year, with inventory turnover rates significantly higher than industry peers [19][21]. - The reduction in inventory was attributed to improved cost control, production efficiency, and the completion of long-term projects, particularly in drug efficacy evaluation and phenotypic analysis [19][21].

公司代码：688265 公司简称：南模生物 上海南方模式生物科技股份有限公司 二〇二五年六月 目 录 议案八 关于调整董事会席位、取消监事会并修订《公司章程》的议案 ..38 上海南方模式生物科技股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保 证大会的顺利进行，根据中国证监会《上市公司股东大会规则》以及《上海南 方模式生物科技股份有限公司章程》（以下简称"《公司章程》"）《上海南 方模式生物科技股份有限公司股东大会议事规则》（以下简称"《股东大会议 事规则》"）的相关规定，特制定 2024 年年度股东大会会议须知： 一、本公司根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》《公司章程》及《股东大会议事规则》的规定，认 真做好召开股东大会的各项工作。 二、本公司设置股东大会会务组，具体负责大会有关程序方面的事宜。 三、本次股东大会以现场会议与网络投票相结合的方式召开。 四、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请 出席现场会议的股东及股东代理人携带相关证件，提前到达会场登记参会资格 并签到。未能提供有效证件并办理签到的，不得参加现 ...